1. Home
  2. LYRA vs SMX Comparison

LYRA vs SMX Comparison

Compare LYRA & SMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LYRA
  • SMX
  • Stock Information
  • Founded
  • LYRA 2005
  • SMX N/A
  • Country
  • LYRA United States
  • SMX Ireland
  • Employees
  • LYRA N/A
  • SMX N/A
  • Industry
  • LYRA Medical/Dental Instruments
  • SMX Industrial Machinery/Components
  • Sector
  • LYRA Health Care
  • SMX Technology
  • Exchange
  • LYRA Nasdaq
  • SMX Nasdaq
  • Market Cap
  • LYRA 5.8M
  • SMX 6.7M
  • IPO Year
  • LYRA 2020
  • SMX N/A
  • Fundamental
  • Price
  • LYRA $24.28
  • SMX $1.22
  • Analyst Decision
  • LYRA Buy
  • SMX
  • Analyst Count
  • LYRA 2
  • SMX 0
  • Target Price
  • LYRA $100.00
  • SMX N/A
  • AVG Volume (30 Days)
  • LYRA 1.9M
  • SMX 59.1K
  • Earning Date
  • LYRA 05-06-2025
  • SMX 12-27-2024
  • Dividend Yield
  • LYRA N/A
  • SMX N/A
  • EPS Growth
  • LYRA N/A
  • SMX N/A
  • EPS
  • LYRA N/A
  • SMX N/A
  • Revenue
  • LYRA $1,185,000.00
  • SMX N/A
  • Revenue This Year
  • LYRA N/A
  • SMX N/A
  • Revenue Next Year
  • LYRA $1,286.17
  • SMX N/A
  • P/E Ratio
  • LYRA N/A
  • SMX N/A
  • Revenue Growth
  • LYRA N/A
  • SMX N/A
  • 52 Week Low
  • LYRA $3.81
  • SMX $1.18
  • 52 Week High
  • LYRA $37.50
  • SMX $438.64
  • Technical
  • Relative Strength Index (RSI)
  • LYRA 76.38
  • SMX 35.02
  • Support Level
  • LYRA $22.22
  • SMX $1.21
  • Resistance Level
  • LYRA $27.42
  • SMX $1.39
  • Average True Range (ATR)
  • LYRA 4.12
  • SMX 0.09
  • MACD
  • LYRA 2.36
  • SMX 0.01
  • Stochastic Oscillator
  • LYRA 60.76
  • SMX 14.29

About LYRA Lyra Therapeutics Inc.

Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.

About SMX SMX (Security Matters) Public Limited Company

SMX (Security Matters) PLC provides one solution to solve both authentication and track and trace challenges in order to uphold supply chain integrity and provide quality assurance and brand accountability to producers of goods. Its technology works as a track and trace system using a marker, a reader, and an algorithm to identify embedded sub-molecular particles in order to track and trace different components along a production process (or any other marked good along a supply chain) to the end producer.

Share on Social Networks: